Key Takeaways
- US generics turned a corner: QoQ revenue grew +11.2% on new launches and acquired brands, and US EBITDA hit its best quarter in the last year, though YoY still declined 12.3% on price erosion.
- The margin recovery is underway but top-line dependent: EBITDA margin improved 160 bps QoQ to double digits; management calls current levels the "absolute nadir" and targets 18–20% over two to three years, but a real shift waits on Spiriva and Darunavir launches.
- Spiriva is the make-or-break catalyst: A first-to-market respiratory generic with a target action date in April or July 2023, it carries substantial top- and bottom-line potential and a competitive runway management estimates at three-plus years.
- India is investing for a Q2 FY24 inflection: Growth trailed the market on diabetes genericization and the Cidmus loss; 1,000 new reps and six divisions are being added now, with above-market growth expected from Q2.
- What to watch next quarter: The Spiriva approval decision, the pace of India's return to double-digit growth, and whether Q4 margins hold at Q3 levels as guided.
US Generics: The Turnaround Thesis
- New launches drove the quarter: Suprep is ramping with a two-player market and nice margins; Perforomist generic capitalized on competitor supply issues; Pennsaid authorized generic also contributed well.
- Respiratory franchise strengthened: Albuterol continued strong performance, joined by acquired brands Brovana and Xopenex (two months of contribution) plus the Perforomist launch.
- Price erosion rationalizing, not ending: Competitive intensity is easing as players exit products and face supply disruptions from margin pressure and GMP issues. High single-digit erosion is the current run-rate and expected to persist through the calendar year.
- Albuterol profitability bought time: It offset significant erosion in the oral solid portfolio, but management expects price pressure over the next two years and has factored that into plans.
- US EBITDA trajectory: Q3 was the best US EBITDA quarter in the last year, pulled up from single digits two quarters ago. Management expects US generics EBITDA to rise above the company average from FY24, subject to Spiriva and Darunavir launches.
- The complex portfolio bet remains unproven: When asked whether Albuterol-level profitability justifies the spend on the complex portfolio given it has not lifted overall profitability, management pointed to new products bolstering the top and bottom line but did not directly address the return on that investment.
Ramesh Swaminathan: "You recognize, Sameer, as well as I do, it was a feast for quite some time. There has been a bit of a famine out there in the last two to three years. But it's not as though this party will never begin again. It will -- so once we get the products in place, things should be much better."
Spiriva & The Pipeline Catalyst Stack
- Spiriva (gSpiriva): Received priority review from the FDA. Target action date is April without an inspection, or July with one. Most disciplines (CMC, PD) are closed; quality is still pending. Management expresses "a great deal of confidence" in first-half approval.
- Competitive runway: Management believes only one competitor has started a PD study, putting any rival at least three years from market, creating a substantial exclusivity window.
- gDiazepam Gel and gNascobal Nasal Spray: Approval expected soon following the recent successful Somerset audit. Both carry exclusivity or first-to-market positioning.
- Darunavir: 600 mg and 800 mg strengths set for Q1 FY24 launch; the larger opportunity is the exclusive strength, with other strengths to follow roughly six months later.
- Pegfilgrastim: Responded to agency queries in recent weeks; management believes all questions are satisfied and expects approval in the next couple of months.
- Injectables pipeline: Four to five products potentially launching in FY24 (Glucagon, Bumetanide, Famotidine, plus products brought in-house to Nagpur), with a larger number the following year.
- Dulera: Received a CRL; additional work is ongoing and the response has not yet been submitted.
- Spiriva inspection uncertainty: When asked why the FDA might need to re-inspect a site already inspected, management called the dual-date language "standard" and could not predict whether an inspection will be required.
Vinita Gupta: "It's April without inspection and July with inspection. So, the FDA decides that they want to come and inspect, then it will -- the TAD date will be July. But if they decide that they don't want to inspect, which is very hard for us to predict, the agency is going to inspect or not, then it's going to likely be April."
India: Investing Through a Soft Patch
- What held India back: Growth fell below market primarily due to the loss of Cidmus from the cardiovascular portfolio and genericization in the diabetes segment (gliptins). Excluding diabetes, Q3 growth was in line with the market.
- Where growth is coming from: Cardiac, GI, and respiratory are all delivering double-digit growth; gynaecology and GI are the fastest-growing therapy areas.
- The diabetes overhang: The India diabetes market is growing at best in the single digits as multiple products genericize. Management's view: if the market bounces back, Lupin will bounce back with it.
- Sales force expansion: Close to 1,000 reps added and six new divisions created. Some staff cost impact will appear in Q4, staggered through the quarter, and is fully baked into numbers from Q1 FY24 onward.
- NLEM impact: Felt at the end of Q3 and will be present in Q4; a good portion is expected to reverse in Q1 FY24.
- Inorganic appetite limited: Acquisitions in India are likely few and far between; bigger targets are at unjustifiable multiples. Management is looking at everything but seeking value.
Nilesh Gupta: "My expectation is that, from the second quarter, we will be growing overall at a rate faster than the market."
Margins: The Long Climb Back
- Q3 margin walk: Gross margin improved to 59.8% (from 58.1% QoQ) on better US mix, reduced freight rates, and lower writeoffs. EBITDA margin rose 160 bps QoQ on higher sales, gross margin, and cost control.
- One-time costs: Manufacturing and other expenses included a roughly INR40 crores base increase from one-time items; this is expected to come down next quarter, possibly offset by an R&D increase.
- Employee cost: Marginal QoQ decline because star club payments were made in Q2. Ongoing basis expected in the 18.5–19% of sales range as the India sales force builds.
- Cost optimization: INR600 crores plan: Progress is mixed. Manpower costs at factories and some lines saw success; other areas were stymied by volume drops leading to inventory writeoffs and impurity issues. Remaining buckets will be achieved, it is only a question of time, and the full INR600 crores benefit will flow into the P&L.
- Q4 margin guidance: EBITDA margin expected in the same range as Q3. A real shift waits on the top line moving with Spiriva, Darunavir, and other launches.
- Medium-term target: Management is confident of reaching 17–18% EBITDA in the next couple of years, with the ultimate goal of getting to the 20% core level that competition is at. R&D as a percent of sales is expected to decline 1–2 percentage points over time.
- Cost contingency: If Spiriva and other products are delayed, expense lines will be reduced; this could shift the EBITDA line perceptibly but not to the extent the top line can.
Ramesh Swaminathan: "Clearly, it's an absolute nadir from my perspective and 18% to 20% over the next two to three years is -- from my perspective is a certainty."
Compliance & Manufacturing Footprint
- Positive regulatory outcomes: Ankleshwar, Nagpur injectables, and Somerset all had positive compliance outcomes. Nagpur received approval after five observations were cleared. Somerset's follow-on inspection was a "very nice win."
- Sites still under pressure: Mandideep and Tarapur are "not at the right level" and "not acceptable." A clear remediation plan is in place and management is committed to getting them to the right spot.
- Workforce optimization: A 16% reduction in manufacturing plant workforce has been executed; R&D workforce has also been optimized.
- Debt increase: Finance costs are elevated because of acquisitions (brands in America and Brazil) plus normal capex. Working capital was reduced but M&A drove debt higher.
Nilesh Gupta: "From the industry perspective, I think there is an over-heightened sensitivity to every 483 that there is. But obviously if there are excessive number of 483s or obviously other regulatory action, that is of concern."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Spiriva approval | Target action date April (without inspection) or July (with inspection); approval expected with "great deal of confidence" | H1 CY2023 |
| Darunavir launch | 600 mg and 800 mg strengths | Q1 FY24 |
| Pegfilgrastim approval | All agency questions believed satisfied | Next couple of months |
| India growth | Grow overall at a rate faster than the market | From Q2 FY24 |
| Q4 FY23 EBITDA margin | In the same range as Q3 | Q4 FY23 |
| US generics EBITDA | Rise above company average level, subject to Spiriva and Darunavir launches | FY24 |
| EBITDA margin target | Reach 17–18%; 18–20% described as "a certainty" | Next 2–3 years |
| R&D expense ratio | Decline 1–2 percentage points as a percent of sales | Over time |
| Cost savings program | Full INR600 crores benefit to flow into P&L | When complete (no date) |
| Injectables launches | Four to five products (Glucagon, Bumetanide, Famotidine, plus in-sourced products) | FY24 |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Revenue | ₹4,244 cr, up 3.7% QoQ and 3.8% YoY |
| Gross margin | 59.8%, up from 58.1% in Q2 FY23; improved US mix and lower freight |
| Operating EBITDA margin (excl. FX and other income) | 12.2%, up 160 bps QoQ on higher sales, gross margins and cost control |
| US business revenue growth (local currency) | 11.2% QoQ, driven by new launches and acquired brands; down 12.3% YoY |
| US quarterly revenue run rate | $170 mn plus with current products, before additional new launches |
| India branded formulations growth | 7.5% in Q3 vs market growth of 10%; grew 2.6% YoY |
| India sales force | 7,100 reps (9,300 total sales force) after adding ~1,000 reps and creating six new divisions |
| New product launch contribution (US) | $20 mn in Q3 revenue from 8 NPLs year-to-date |
| API business growth | 12.7% QoQ, 9.8% YoY, led by cephalosporins recovery |
| EMEA revenue growth | 11.1% YoY, driven by Luforbec in UK and NaMuscula in Germany |
| Growth Markets revenue growth | 23.5% YoY; declined 5.9% QoQ |
| Employee benefit cost | ₹764 cr, marginally down from ₹771 cr in Q2 FY23; ongoing range expected at 18.5%–19% of sales |
| Net debt | ₹3,400 cr; gross debt at ₹4,600 cr, reflecting brand acquisitions and capex |
| R&D expense | ~8% of sales for FY23, expected to decline by 1–2 ppt over time |